State of New Jersey Common Pension Fund D acquired a new position in Celcuity, Inc. (NASDAQ:CELC – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 4,344 shares of the company’s stock, valued at approximately $433,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Simplicity Wealth LLC purchased a new position in shares of Celcuity in the fourth quarter worth about $580,000. M&T Bank Corp lifted its stake in shares of Celcuity by 14.3% during the 4th quarter. M&T Bank Corp now owns 4,671 shares of the company’s stock valued at $465,000 after buying an additional 583 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Celcuity by 10.7% in the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after buying an additional 220,386 shares during the period. NBC Securities Inc. purchased a new position in Celcuity in the 4th quarter valued at approximately $99,000. Finally, Arizona State Retirement System purchased a new position in Celcuity in the 4th quarter valued at approximately $359,000. 63.33% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on CELC shares. Citizens Jmp boosted their target price on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a report on Monday, May 4th. Guggenheim lifted their price target on Celcuity from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research note on Monday, May 4th. Craig Hallum reissued a “buy” rating and set a $189.00 price objective on shares of Celcuity in a report on Monday, May 4th. Finally, Stifel Nicolaus set a $150.00 target price on Celcuity in a research note on Monday, May 4th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $134.50.
Insider Activity
In other news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares of the company’s stock, valued at $9,144,200. The trade was a 27.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 37,000 shares of company stock worth $5,111,950. Insiders own 13.33% of the company’s stock.
Celcuity Trading Down 4.1%
Celcuity stock opened at $125.64 on Tuesday. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. Celcuity, Inc. has a fifty-two week low of $9.51 and a fifty-two week high of $151.02. The stock has a market cap of $6.07 billion, a P/E ratio of -33.15 and a beta of 0.09. The firm’s fifty day moving average price is $117.22 and its 200-day moving average price is $105.30.
Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.09. Equities research analysts forecast that Celcuity, Inc. will post -3.87 earnings per share for the current fiscal year.
Celcuity Company Profile
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Featured Stories
- Five stocks we like better than Celcuity
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
